Table 2.
Clinical Findings and Treatment Course of the Study Cohort.
| Total cohort (n = 22) | Non-MV (n = 15) | MV (n = 7) | |
|---|---|---|---|
| Presenting Signs and Symptoms (n, %) | |||
| Fever | 17 (77) | 12 80) | 5 (71) |
| Cough | 11 (50) | 9 (60) | 2 (29) |
| Dyspnea | 7 (32) | 4 (27) | 3 (43) |
| Diarrhea | 4 (18) | 4 (27) | 0 |
| Hypoxemia | 16 (73) | 9 (60) | 7 (100) |
| APACHE-II (median, IQR) | 27 (21-34) | ||
| ICU Admission (n, %) | 8 (36) | 1 (7) | 7 (100) |
| COVID-19 Specific Treatments (n, %) | |||
| Hydroxychloroquine | 17 (77) | 11 (73) | 6 (86) |
| Azithromycin | 10 (45) | 4 (27) | 6 (86) |
| Corticosteroids | 3 (14) | 2 (13) | 1 (14) |
| Tocilizumab | 1 (5) | 0 | 1 (14) |
| Anakinra | 1 (5) | 1 (7) | 0 |
| Length of Stay (days, mean, SD) 1 | 11.1 ± 6.7 | ||
| Vital Status (n, %) | |||
| Alive | 15 (68) | 14 (93) | 1 (14) |
| Deceased | 7 (32) | 1 (7) | 6 (86) |
1Calculated for patients discharged alive.